Emergency stroke treatment drug ‘Tenecte Place’ has better treatment results than ‘Alte Place’

[메디컬투데이=이승재 기자] A study showed that, among the thrombolytics used for stroke, ‘Tenecteplace’ had better treatment results than the previously approved drug ‘Alteplace’.

The results of a study comparing functional outcomes after the use of Tenecteplace and Alteplace in stroke patients were published in the journal Neurology.

Stroke is a leading cause of death and a leading cause of physical disability worldwide. The most common type of stroke is an ischemic stroke, which occurs when a blood clot blocks a cerebral blood vessel.

Thrombolytics are medications that are given as an emergency within a few hours of the onset of stroke symptoms. Currently, the only drug approved for acute ischemic stroke is ‘Alteplace’, a tissue plasminogen activator (tPA) class. However, health organizations such as the European Stroke Group have also recommended the use of ‘Tenecteplace’, another tPA drug, instead of Alteplace.

The researchers analyzed data from 3,788 patients who received Tenecteplace and 3,757 patients who received Alteplace from 11 related literature and compared the effectiveness and safety of Alteplace and Tenecteplace within 4 hours and 30 minutes of initiation stroke symptoms.

The main outcome indicator that the researchers focused on was the extent to which physical activity was back three months after the stroke.

As a result of the study, patients who received Tenecteplace had better physical activity and a lower risk of physical disability 3 months after the stroke compared to patients who received Alteplace. However, safety, all-cause mortality, and incidence of symptomatic intracranial hemorrhage were similar.

In addition, the researchers conducted a trial series analysis (TSA) to determine the efficacy of Tenecteplace. As a result, stroke treatment outcomes were significantly better at Tenecte Place than Alte Place.

Based on these results, the researchers concluded that among the thrombolytic drugs used to treat stroke, Tenecteplace had better functional results than Alteplace.

Medical Today Reporter Seungjae Lee ([email protected])

[저작권자ⓒ 메디컬투데이. 무단전재-재배포 금지]